BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35675604)

  • 21. The effectiveness of relugolix compared with leuprorelin for preoperative therapy before laparoscopic myomectomy in premenopausal women, diagnosed with uterine fibroids: protocol for a randomized controlled study (MyLacR study).
    Kitade M; Kumakiri J; Kobori H; Murakami K
    Trials; 2024 May; 25(1):343. PubMed ID: 38790029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.
    Muhammad J; Yusof Y; Ahmad I; Norhayati MN
    BMC Womens Health; 2022 Jan; 22(1):14. PubMed ID: 35033041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials: Correction.
    Obstet Gynecol; 2022 Jul; 140(1):138. PubMed ID: 35849476
    [No Abstract]   [Full Text] [Related]  

  • 24. Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas: A Randomized Controlled Trial.
    Brown E; Kroll R; Li H; Ng J; Pinsky B; Rodriguez JW; Thomas J; Snabes MC
    Obstet Gynecol; 2023 Nov; 142(5):1068-1076. PubMed ID: 37769311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
    Blair HA
    Drugs; 2024 Apr; 84(4):449-457. PubMed ID: 38592603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
    Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
    Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis.
    Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Dynowski K; Wilk K; Li Y; Mathur V; Wagman RB; Johnson NP
    Pain Manag; 2023 Nov; 13(11):631-640. PubMed ID: 37982388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.
    Al-Hendy A; Zhou YF; Faustmann T; Groettrup-Wolfers E; Laapas K; Parke S; Seitz C
    F S Sci; 2023 Nov; 4(4):317-326. PubMed ID: 37437885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy.
    Sasamori Y; Takehara K; Terashima T; Onodera T; Yatsuki K; Nakagawa I; Takahashi Y; Nishida H; Ichinose T; Hiraike H; Nagasaka K
    BMC Womens Health; 2021 Aug; 21(1):306. PubMed ID: 34412607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
    Murji A; Whitaker L; Chow TL; Sobel ML
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.
    Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
    BMC Womens Health; 2021 Jun; 21(1):250. PubMed ID: 34154590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
    Neblett MF; Stewart EA
    Obstet Gynecol; 2023 May; 141(5):901-910. PubMed ID: 37103532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
    Donnez J; Taylor HS; Stewart EA; Bradley L; Marsh E; Archer D; Al-Hendy A; Petraglia F; Watts N; Gotteland JP; Bestel E; Terrill P; Loumaye E; Humberstone A; Garner E
    Lancet; 2022 Sep; 400(10356):896-907. PubMed ID: 36116480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis.
    Arjona Ferreira JC; Migoya E
    F S Rep; 2023 Jun; 4(2 Suppl):73-82. PubMed ID: 37223761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
    Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
    Fertil Steril; 2021 Feb; 115(2):397-405. PubMed ID: 32912633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study.
    Wada Y; Takei Y; Minezumi T; Hirashima H; Fujiwara H
    BMC Womens Health; 2023 Mar; 23(1):110. PubMed ID: 36922784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relugolix for the treatment of uterine fibroids.
    Rocca ML; Palumbo AR; Lico D; Fiorenza A; Bitonti G; D'Agostino S; Gallo C; Di Carlo C; Zullo F; Venturella R
    Expert Opin Pharmacother; 2020 Oct; 21(14):1667-1674. PubMed ID: 32674616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids.
    Stewart EA; Archer DF; Owens CD; Barnhart KT; Bradley LD; Feinberg EC; Gillispie-Bell V; Imudia AN; Liu R; Kim JH; Al-Hendy A
    J Womens Health (Larchmt); 2022 May; 31(5):698-705. PubMed ID: 34582715
    [No Abstract]   [Full Text] [Related]  

  • 39. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
    Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
    Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
    Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.